Cite
MA04.05 Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma
MLA
Dao M. Nguyen, et al. “MA04.05 Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma.” Journal of Thoracic Oncology, vol. 16, Oct. 2021, pp. S897–98. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........76cc5dc93e394b89ec47d97edfbfbf61&authtype=sso&custid=ns315887.
APA
Dao M. Nguyen, Ahmed Alnajar, Nestor Villamizar, S. Razi, & Estelamari Rodriguez. (2021). MA04.05 Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 16, S897–S898.
Chicago
Dao M. Nguyen, Ahmed Alnajar, Nestor Villamizar, S. Razi, and Estelamari Rodriguez. 2021. “MA04.05 Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma.” Journal of Thoracic Oncology 16 (October): S897–98. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........76cc5dc93e394b89ec47d97edfbfbf61&authtype=sso&custid=ns315887.